GBIO is expected to report earnings to rise 19.96% to -27 cents per share on February 20
Q4'24
Est.
$-0.28
Q3'24
Beat
by $0.04
Q2'24
Missed
by $0.04
Q1'24
Missed
by $0.72
Q4'23
Missed
by $0.07
The last earnings report on November 07 showed earnings per share of -23 cents, beating the estimate of -27 cents. With 196.06K shares outstanding, the current market capitalization sits at 112.21M.
a genetic medicines company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases